| Study |
Reference |
|
Källén (control exposed to ergots), 2011
|
K?ll?n B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703
|
|
Källén (control unexposed, disease free), 2011
|
K?ll?n B Delivery outcome after maternal use of drugs for migraine: a register study in Sweden. Drug Saf 2011;34:691-703
|
|
Nezvalová-Henriksen (Control unexposed, disease free), 2013
|
Nezvalova-Henriksen K Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69
|
|
Nezvalová-Henriksen (Control unexposed, sick), 2013
|
Nezvalova-Henriksen K Triptan safety during pregnancy: a Norwegian population registry study. Eur J Epidemiol 2013;28:759-69
|
|
Spielmann (Control mainly exposed other treatments, sick), 2017
|
Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152
|
|
Spielmann (Control unexposed, disease free), 2017
|
Spielmann K Pregnancy outcome after anti-migraine triptan use: A prospective observational cohort study. Cephalalgia 2017;:333102417724152
|
